Gene Cell Therapy CDMO Market (By Product Type: Cell Therapy, Gene-Modified Cell Therapy; By Service Type: Contract Manufacturing, Process Development; By Indication: Oncology, Rare Genetic Diseases; By Region: North America, LAMEA, Europe, Asia-Pacific) Industry Size, Share, Growth, Trends 2026 to 2035.
The global Gene Cell Therapy CDMO market was valued at USD 2.50 billion in 2025 and is projected to reach approximately USD 5.35 billion by 2035, growing at a robust CAGR of 7.90%. This expansion is driven by advancements in personalized medicine, increasing demand for innovative therapies, and strategic investments in biomanufacturing capabilities.
| Reports Attributes | Statistics |
| Market Size in 2025 | USD 2.50 Billion |
| Market Size in 2026 | USD 2.70 Billion |
| Market Size in 2032 | USD 4.26 Billion |
| Market Size by 2035 | USD 5.35 Billion |
| CAGR 2026 to 2035 | 7.90% |
| Base Year | 2025 |
| Forecast Period | 2026 to 2035 |
The growing need for expertise and scalability, along with the promising tech advancements for further valuable integrations hypes the market growth. This market is a collaborator that delivers outsourced services to the drug creators for new advanced therapies to add on in the extensive market and the giant’s pipeline. It encompasses cell therapy production, viral vector manufacturing, and more.
| Segments | Shares (%) |
| North America | 45% |
| Europe | 25% |
| Asia Pacific | 20% |
| LAMEA | 10% |
| Segments | Shares (%) |
| Cell Therapy | 60% |
| Gene-Modified Cell Therapy | 40% |
| Segments | Shares (%) |
| Contract Manufacturing | 70% |
| Process Development | 30% |
| Segments | Shares (%) |
| Oncology | 60% |
| Rare Genetic Diseases | 40% |
Published by Yogesh Kulkarni
